A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
Kai Zhao(Philipps University of Marburg), Tillmann Rusch(Goethe University Frankfurt)
Cited by 4
Related Papers
RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner
|Cell Death and Disease|2019|73
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
|Scientific Reports|2016|61
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
|International Journal of Molecular Sciences|2021|30
Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
|Biomedicines|2022|4
Comprehensive genome editing and signaling pathway engineering evolve potent and safe adenoviral producer cell
|Communications Biology|2026|0